4-Hydroxy-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one | 356571-75-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 4-Hydroxy-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one
• 英文别名: 2 inverted exclamation mark,3 inverted exclamation mark-Dideoxyuridine；1-[5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• CAS: 356571-75-0
• 化学式: C₉H₁₂N₂O₄
• mdl: MFCD02330821
• 分子量: 212.205
• InChiKey: BTOTXLJHDSNXMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-Hydroxy-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one 在 磷酸三甲酯 、 三氯氧磷 作用下， 反应 24.0h， 生成 trans-1-(D,L-5-hydroxymethyl-2-tetrahydrofuryl)uracil 5'-phosphate 、 cis-1-(D,L-5-hydroxymethyl-2-tetrahydrofuryl)uracil 5'-phosphate
  参考文献：
  名称：

  嘧啶核苷的类似物。16.外消旋的2'，3'-二脱氧核苷及其衍生物

  摘要：

  DOI：

  10.1007/bf00513297

文献信息

• [EN] MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS OLIGOMÈRES MODIFIÉS ET LEURS UTILISATIONS
  申请人：IONIS PHARMACEUTICALS INC

  公开号：WO2021030763A1

  公开（公告）日：2021-02-18

  The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside. An oligomeric compound comprising a modified oligonucleotide consisting of 12-30 linked nucleosides, wherein at least one nucleoside of the modified oligonucleotide is a stereo-non-standard nucleoside; and wherein the oligomeric compound is selected from among an RNAi compound, a modified CRISPR compound, and an artificial mRNA compound.

  本公开提供了包含至少一种立体非标准核苷酸的修饰寡核苷酸的寡聚化合物。包括由12-30个连接的核苷酸组成的修饰寡核苷酸的寡聚化合物，其中修饰寡核苷酸的至少一个核苷酸是立体非标准核苷酸；且所述寡聚化合物选自RNAi化合物、修饰CRISPR化合物和人工mRNA化合物。
• [EN] NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSITIONS D'ACIDE NUCLÉIQUE-POLYPEPTIDE ET UTILISATIONS DE CELLES-CI
  申请人：AVIDITY BIOSCIENCES LLC

  公开号：WO2019071028A1

  公开（公告）日：2019-04-11

  Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

  本文披露了包含与修饰的多核苷酸分子和聚合物结合基团的组合物和药物配方。本文还描述了利用包含与多核苷酸分子和聚合物结合基团共轭的组合物或药物配方治疗癌症的方法。
• [EN] UNA AMIDITES AND USES THEREOF<br/>[FR] AMIDITES D'UNA ET LEURS UTILISATIONS
  申请人：AVIDITY BIOSCIENCES INC

  公开号：WO2020247818A1

  公开（公告）日：2020-12-10

  Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a disease which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

  本文披露了包含结合基团与修饰的多核苷酸分子和聚合物结合的组合物和药物配方。本文还描述了利用包含结合基团与多核苷酸分子和聚合物结合的组合物或药物配方进行治疗疾病的方法。
• [EN] SYNTHESIS OF FLUORINATED NUCLEOTIDES<br/>[FR] SYNTHÈSE DE NUCLÉOTIDES FLUORÉS
  申请人：MERCK SHARP & DOHME

  公开号：WO2022035917A1

  公开（公告）日：2022-02-17

  The present invention relates to efficient processes useful in the preparation of fluorinated nucleosides, such as (O-[(2R,3R,4S,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-3-hydroxyoxolan-2-yl]methyl}O,O-dihydrogen phosphorothioate, also known as 2'-(S)-fluoro-thio-adenosine monophosphate or 2'-F-thio-AMP. Such fluorinated nucleosides may be useful as a biologically active compound and or as an intermediate for the synthesis of more complex biologically active compounds. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.

  本发明涉及有效的过程，用于制备氟代核苷，例如（O-[(2R,3R,4S,5R)-5-(6-氨基-9H-嘌呤-9-基)-4-氟-3-羟基氧杂环己烷-2-基]甲基}O，O-二氢磷酸硫酯，也称为2'-(S)-氟硫腺苷酸单磷酸酯或2'-F-硫-AMP。这种氟代核苷可以用作生物活性化合物，或用作更复杂生物活性化合物的合成中间体。本发明还涵盖了在所披露的合成过程中有用的中间体及其制备方法。
• [EN] SYNTHESIS OF ANTIVIRAL NUCLEOSIDES<br/>[FR] SYNTHÈSE DE NUCLÉOSIDES ANTIVIRAUX
  申请人：MERCK SHARP & DOHME

  公开号：WO2022133205A1

  公开（公告）日：2022-06-23

  The present invention relates to efficient synthetic processes useful in the preparation of antiviral nucleosides, particularly uridine 4-oxime 5'-(2-methylpropanoate) (2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]oxolan-2-yl}methyl 2-methylpropanoate and pharmaceutically acceptable salts, derivatives, tautomers, isomers, and prodrugs of, which may be active as antiviral agents, as well as compositions and methods thereof. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.

  本发明涉及高效合成过程，用于制备抗病毒核苷类物质，特别是尿嘧啶4-肟5'-(2-甲基丙酸酯)(2R,3S,4R,5R)-3,4-二羟基-5-[4-(羟肟基)-2-氧代-3,4-二氢嘧啶-1(2H)-基]氧戊-2-基}甲基2-甲基丙酸酯及其药学上可接受的盐、衍生物、互变异构体、同分异构体和前药，可能作为抗病毒剂活性，以及其组合物和方法。本发明还包括在所述的合成过程中有用的中间体及其制备方法。